Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration

NCT00423189 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

7

Enrollment

OTHER

Sponsor class

Stopped Lack of efficacy

Conditions

Age-Related Macular Degeneration

Interventions

DRUG: Ranibizumab (Lucentis)
DRUG: 0.5mg ranibizumab

Sponsor

David M. Brown, M.D.

Collaborators

[object Object]